Voloridge Investment Management, LLC Mirati Therapeutics, Inc. Transaction History

Voloridge Investment Management, LLC

$26.2 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$27.8 - $45.35 $10.5 Million - $17.2 Million	-379,428 Reduced 93.45%	26,607 $1.16 Million
Q2 2023 Aug 14, 2023	SELL	$36.13 - $49.49 $9.85 Million - $13.5 Million	-272,623 Reduced 40.17%	406,035 $14.7 Million
Q1 2023 May 15, 2023	BUY	$36.54 - $54.26 $19.1 Million - $28.4 Million	524,038 Added 338.92%	678,658 $25.2 Million
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $5.38 Million - $12.9 Million	130,363 Added 537.42%	154,620 $7.01 Million
Q3 2022 Nov 14, 2022	SELL	$59.5 - $86.7 $22.4 Million - $32.6 Million	-375,923 Reduced 93.94%	24,257 $1.69 Million
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $13.3 Million - $30.1 Million	339,781 Added 562.56%	400,180 $26.9 Million
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $4.58 Million - $9.12 Million	60,399 New	60,399 $4.97 Million
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $610,704 - $820,173	-4,622 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$144.0 - $179.73 $2.81 Million - $3.5 Million	-19,496 Reduced 80.84%	4,622 $747,000
Q1 2021 May 17, 2021	BUY	$158.92 - $221.61 $1.58 Million - $2.2 Million	9,948 Added 70.2%	24,118 $4.13 Million
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $344,032 - $510,093	2,123 Added 17.62%	14,170 $3.11 Million
Q3 2020 Nov 16, 2020	BUY	$113.26 - $167.27 $1.36 Million - $2.02 Million	12,047 New	12,047 $2 Million
Q3 2019 Nov 14, 2019	SELL	$77.91 - $109.6 $2.26 Million - $3.19 Million	-29,071 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$59.49 - $104.71 $410,837 - $723,127	-6,906 Reduced 19.2%	29,071 $2.99 Million
Q1 2019 May 15, 2019	BUY	$43.65 - $78.95 $1.57 Million - $2.84 Million	35,977 New	35,977 $2.64 Million

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Voloridge Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voloridge Investment Management, LLC with notifications on news.

Account